Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, WI, USA.
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, WI, USA.
Ann Diagn Pathol. 2021 Dec;55:151801. doi: 10.1016/j.anndiagpath.2021.151801. Epub 2021 Jul 31.
Although pheochromocytomas and paragangliomas (PPGLs) are usual low-grade neoplasms, the metastatic forms of these lesions are associated with high morbidity and mortality. Recent studies have discovered multiple aberrantly expressed long non-coding RNAs (lncRNAs) in cancers that may have regulatory roles in tumor pathogenesis and metastasis; however, the roles of some lncRNAs in PPGLs are still unknown. The expression levels of lncRNAs including metastasis-associated lung adenocarcinoma transcript (MALAT1), prostate cancer antigen 3 (PCA3), and HOX transcript antisense intergenic RNA (HOTAIR) in PPGLs were analyzed by in situ hybridization, using two tissue microarrays (TMAs). The pheochromocytoma (PCC) TMA consisted of normal adrenal medulla (N = 25), non-metastatic PCCs (N = 76) and metastatic PCCs (N = 5) while the paraganglioma (PGL) TMA had 73 non-metastatic PGLs and 5 metastatic PGLs. Immunohistochemical staining was performed on all samples with an anti-SDHB antibody. The correlations between lncRNA expression, loss of SDHB expression and clinical characteristics including tumor progression and disease prognosis were investigated. The expression levels of MALAT1 and PCA3 were significantly elevated (2.5-3.9 folds) in both non-metastatic and metastatic PCCs compared to normal adrenal medulla, although there were no significant differences between the non-metastatic and metastatic neoplasms. In contrast to non-metastatic PGLs, metastatic PGLs had significantly upregulated expression of MALAT1, PCA3, and HOTAIR. SDHB loss was more frequently observed in PGLs (25 of 78), especially in metastatic PGLs (5 of 5), compared to PCCs (2 of 81) and in 0 of 5 metastatic PCCs. Patients with SDHB loss, in contrast to SDHB retained, were younger at diagnosis, had higher rates of tumor recurrence, metastatic disease, and mortality. In addition, PGLs with SDHB loss had significantly increased expression of PCA3 compared to tumors with intact SDHB expression. Our findings suggest that specific lncRNAs may be involved in the SDHx signaling pathways in the tumorigenesis and in the development of PPGL.
尽管嗜铬细胞瘤和副神经节瘤(PPGL)通常是低度恶性肿瘤,但这些病变的转移性形式与高发病率和死亡率相关。最近的研究发现,癌症中存在多种异常表达的长链非编码 RNA(lncRNA),它们可能在肿瘤发病机制和转移中具有调节作用;然而,一些 lncRNA 在 PPGL 中的作用仍不清楚。通过原位杂交分析了包括转移相关肺腺癌转录物(MALAT1)、前列腺癌抗原 3(PCA3)和 HOX 转录反义基因间 RNA(HOTAIR)在内的 lncRNA 在 PPGL 中的表达水平,使用了两个组织微阵列(TMA)。嗜铬细胞瘤 TMA 由正常肾上腺髓质(N=25)、非转移性嗜铬细胞瘤(N=76)和转移性嗜铬细胞瘤(N=5)组成,而副神经节瘤 TMA 有 73 例非转移性副神经节瘤和 5 例转移性副神经节瘤。对所有样本进行了抗 SDHB 抗体的免疫组织化学染色。研究了 lncRNA 表达、SDHB 表达缺失与肿瘤进展和疾病预后等临床特征之间的相关性。MALAT1 和 PCA3 的表达水平在非转移性和转移性嗜铬细胞瘤中均显著升高(2.5-3.9 倍),与正常肾上腺髓质相比,尽管在非转移性和转移性肿瘤之间没有显著差异。与非转移性副神经节瘤相比,转移性副神经节瘤中 MALAT1、PCA3 和 HOTAIR 的表达显著上调。与嗜铬细胞瘤(81 例中 2 例)相比,副神经节瘤(78 例中 25 例),尤其是转移性副神经节瘤(5 例)中更频繁地观察到 SDHB 缺失,而 5 例转移性嗜铬细胞瘤中无 SDHB 缺失。与保留 SDHB 的患者相比,SDHB 缺失的患者在诊断时更年轻,肿瘤复发、转移性疾病和死亡率更高。此外,与 SDHB 表达完整的肿瘤相比,SDHB 缺失的副神经节瘤 PCA3 的表达显著增加。我们的研究结果表明,特定的 lncRNA 可能参与了 SDHx 信号通路在 PPGL 发生和发展中的作用。